Expert Series: Stereo-Selectivity in Drug Metabolism

 

Speaker: James Schmidt

j.James Schmidt is the EAG Life Sciences Senior Scientific Advisor for Custom Synthesis, Trace Analysis and Structural Chemistry, and Product Chemistry.

James attended Benedictine College (Atchison, KS) where he studied chemistry and philosophy; he received his B.S. in Chemistry (ACS Certified) from the University of Central Oklahoma and completed supporting graduate work in environmental impact assessment at the University of Oklahoma.

James brings nearly three decades of experience in xenobiotic metabolism, bio-analytical chemistry, and structural elucidation with private, government, and industrial laboratories, with positions at the USEPA’s Kerr Groundwater Research Laboratory (Ada, OK), Sandoz Agro (Des Plaines, IL), Abbott Laboratories (Abbott Park, IL), Lexicon Pharmaceuticals (The Woodlands, TX), and presently as a Sr. Scientific Advisor (SSA) at ABC Labs (Columbia, MO).

His special interests include small molecule metabolic stability, metabolite profiling and identification, chiral separations, and pharmacologically active metabolites.  He is the author or co-author of several peer-reviewed posters and papers, as well as innumerable scientific reports to satisfy regulatory requirements of both the EPA and FDA. Most recently, he contributed the chapter on “Metabolite Profiling” to the book New Horizons in Predictive Drug Metabolism and Pharmacokinetics (Alan G. E Wilson, ed., RSC Publishing, 2015). James is based at EAG’s Columbia, Missouri (formerly ABC Laboratories) location.

In this webinar: James discuss how  there are few aspects of drug metabolism and metabolite profiling more essential – and more interesting – than exploring stereo-selective metabolism. For the better part of a century, the consideration of chirality in drug metabolism was limited to academic study and/or to natural products, owing in no small part to the limits of separations chemistry. However, chirality has been earning ever- greater importance in drug discovery and development, such that most of the new molecular entities reaching the market in the first decades of the 21st century are single enantiomers, rather than the racemic mixtures (or achiral drugs) that dominated the latter half of the 20th century. Stereo-selective metabolism has important impacts on scientific aspects such as pharmacokinetics, pharmacodynamics, drug safety, and bio-analytical chemistry; but also on regulatory, intellectual property, business and product development, and other important considerations. In this webinar you will view examples of typical stereo-selective metabolism reactions, potential drug-drug interactions, and bio-analytical chemistry approaches. A case study of stereo-selective metabolism and metabolite profiling will also be presented, with important questions to consider.

Register Now

 

For more webinars from our expert series click here